Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,231,650.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $550.70, for a total transaction of $5,231,650.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $178,670,760.10. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $6.70 during midday trading on Tuesday, reaching $543.40. The company’s stock had a trading volume of 504,426 shares, compared to its average volume of 554,931. The stock has a market capitalization of $23.31 billion, a P/E ratio of 19.44, a PEG ratio of 2.73 and a beta of 0.49. The firm has a 50 day moving average price of $512.67 and a 200-day moving average price of $540.26. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. During the same period last year, the business posted $6.41 earnings per share. On average, equities analysts predict that United Therapeutics Corporation will post 26.40 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. The Goldman Sachs Group started coverage on shares of United Therapeutics in a research report on Thursday, September 24th. They set a “sell” rating and a $321.00 price target for the company. Morgan Stanley raised their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $627.31.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in United Therapeutics in the 2nd quarter worth about $2,868,735,000. Janus Henderson Group PLC lifted its holdings in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the last quarter. Jupiter Topco LLC purchased a new stake in United Therapeutics during the second quarter valued at about $450,140,000. Swedbank AB lifted its holdings in United Therapeutics by 0.7% during the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock valued at $193,977,000 after purchasing an additional 2,350 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its position in United Therapeutics by 0.8% during the first quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company’s stock worth $183,306,000 after purchasing an additional 2,383 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.